Don't miss out on the latest news, evidence and CPD opportunities on medicines and medical tests - sign up today.
You have not selected any filters.
Access free accredited CPD activities – independent, evidence based and peer reviewed – designed to keep you up-to-date with the latest in prescribing practice.
Confidently recognise when low back pain requires further investigation and identify patients at risk of chronic, disabling pain.
Review your PPI prescribing for patients with GORD and be guided on implementing an effective step-down approach for your patients.
How would you advise a patient with well-controlled gastro-oesophageal reflux disease (GORD) who would like to continue their proton pump inhibitor (PPI) therapy?
Optimal management of patients with rheumatoid arthritis depends on successful collaboration between rheumatologists, GPs and community pharmacists.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for people with diabetes and the largest contributor to the direct and indirect costs of diabetes. Approximately 65% of all CVD deaths in Australia occur in people with diabetes or prediabetes.Over the last few years, the management of type 2 diabetes has rapidly grown more complex. Recent developments include new medicines, emerging clinical trial results that provide cardiovascular (CV) outcome data related to blood glucose-lowering medicines, and an update to clinical guidelines. Now, more than ever, a clear, stepped approach is necessary to navigate the plethora of options available and reduce risk of microvascular and macrovascular complications.This webinar has been developed in partnership with the Australian Diabetes Society.This program is funded by Boehringer Ingelheim Pty Limited and Eli Lilly Australia Pty Limited and managed through VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The program has been designed, developed and implemented by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.
Warfarin and the new oral anticoagulants are licensed for non-valvular atrial fibrillation and venous thromboembolism. The choice of anticoagulant depends on the characteristics of the patient and the medicine. Paul KL Chin, Aust Prescr 2016;39:200-4